| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $150.8M | +153.5% |
| SG&A Expense | $60.5M | +100.0% |
| Operating Income | -$226.0M | +62.9% |
| Pre-tax Income | -$221.3M | +64.0% |
| Net Income | -$221.3M | +64.0% |
| EPS (Basic) | -$0.31 | +68.7% |
| EPS (Diluted) | -$0.31 | +68.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $104.9M | +46.8% |
| Short-term Investments | $307.5M | +167.8% |
| Current Assets | $423.8M | +123.4% |
| Total Assets | $435.6M | +114.6% |
| Current Liabilities | $41.7M | +104.5% |
| Total Liabilities | $46.8M | -62.6% |
| Stockholders' Equity | $388.7M | +400.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$142.1M | -85.1% |
| Capital Expenditures | $139K | +8.6% |
| Investing Cash Flow | -$205.3M | +65.1% |
| Financing Cash Flow | $381.2M | +340.7% |
| Free Cash Flow | -$142.2M | -85.0% |